MARCH, 2021 UPDATE

Pharmachal Health Group is a Melbourne-based pharmaceutical company that exclusively licences a certified globally- patented mini-emulsion drug-in-oil delivery methodology ("Nano Drug Delivery System" or "NDDS") capable of delivering a wide range of APIs (drugs / other active ingredients) topically, sublingually, or rectally.

Highlights

During the Quarter Pharmachal Health Group:

- Directed the contract manufacturer to initiate the third and final commercial-scale batch of NOPAYNE, the last 'step up' batch required before submission to the TGA. This is a massive milestone for the company and paves the way to launch of NOPAYNE in the second half of the year.
- Initiated orders for three over-the-counter dermal products, allowing PHG to take them to market in the next 6 – 8 weeks.
- Cemented its equity position in NS Technologies, coming to terms and making a down-payment to acquire 90% of the related company holding the NDDS patents.
- Further developed its relationship with a Canadian pharma group to explore co-development and marketing of products. Licencing agreements have been discussed to have products manufactured under licence in Canada for the North American market.
- Deepened ongoing discussions with a Swiss / South African company to register the anti-viral flu / Covid-19 drug Triazavirin™ - Riamilovir – TZV in Australia.

About Triazavirin™ - Riamilovir – (TZV™)

Triazavirin™ - Riamilovir – (TZV™) is an anti-viral drug that has been registered to treat Influenza A&B. Data supplied out of China (Heilongjiang Province) in a placebo-controlled clinical trial, along with experience of treatment of 214 patients treated by the FMBA in Russia, provides valuable insight into the efficacy of the product.

TZV™ has been adopted into the Standards of Care by the Moscow and Sverdlovsk MOHs for the treatment of COVID-19. Apart from the above clinical trial data, additional clinical information (which has not yet been published) has demonstrated that patients treated with TZV™ will typically show rtPCR negative results after 14 days after commencing treatment. Furthermore, with a limited dose all patients' lung lesions clear after 28 days. LDH is also decreased in patients who have used TZV™. Importantly, clinical febrile symptoms are typically also relieved within 3 days of TZV™ treatment.

For more information please visit our page on the Funding Strategies website (Project Levatio) or contact Funding Strategies via email or phone +61 7 3160 2840.

Charles Fridlender
Director

19 March 2021